Trials / Completed
CompletedNCT01220518
Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in AS Patients(PLANETAS)
Randomized, Double-blind, Parallel-group, Phase 1 Study
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 257 (actual)
- Sponsor
- Celltrion · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is the trial to demonstrate how our product is similar to remicade by comparing the results of blood samples in active Ankylosing Spondylitis patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Infliximab | Infliximab 5mg/kg is going to be administered for both arm as a 2-hour infusion per dose. |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2011-11-01
- Completion
- 2012-06-01
- First posted
- 2010-10-14
- Last updated
- 2013-03-12
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01220518. Inclusion in this directory is not an endorsement.